Regenics shareholders as of August 29th 2016

 

SHARES

%

Collas AS

1895

3,98

Runhild Gammelsæter

942

1,98

Camilla Haglerød

220

0,46

Rune Nilsen

1023

2,15

Life Capitol AS

13240

27,78

Greyston Holding AS

965

2,02

Heldrup AS

18478

38,77

Marcus Heldrup

829

1,74

Cornucopia AS

5245

11,00

Intento AS

4179

8,77

Gry Lønne Eriksson

650

1,36

 

 

 

SUM

47666

100,00

 

Collas AS : Philippe Collas, Founder and Board member

Runhild Gammelsæter: former CEO, private

Camilla Haglerød: former CEO, private

Rune Nilsen: private

Life Capitol AS: Jan Remmereit, founder, Board member

Greystone Holding AS: Jan Remmereit

Heldrup AS: Tore Heldrup Rasmussen, founder, Chairman Board

Markus Heldrup: Head of production, CPO, employee

Cornucopia AS: Henrik Lund, CEO, consultant

Inento AS: Christian Clemm, CMO, employee

Gry Lønne Eriksson:  Gry Lønne Eriksson, CSO, employee

 

Planned/completed share issues:

2015: Gross proceeds 1.0 mill NOK 

2016: Gross proceeds 1.72 mill NOK

2017: Gross proceeds 1.0 mill NOK (August)

(2017: Planned proceeds > 10 mill NOK at q2-q3 ),

for more info see Protocols Annual Meetings below:

Protocol Annual Meeting 2015, June 22 2015

Protocol Annual Meeting 2016, June 22 2016

Protocol Extraordinary Annual Meeting 2016, July 11th 2016

Protocol Annual Meeting 2017, June 27 2017

Regenics AS has developed a number of assays and techniques to study effects of various substances on skin cells both in vitroin vivo and in the clinic. Our focus is to develop products and techniques for therapeutic skin applications and to improve skin appearance.